⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786900 | 0.86 | — | — | |
| SCHEMBL946850 | 0.86 | — | — | |
| SCHEMBL8052 | 0.84 | — | — | |
| SCHEMBL21811189 | 0.73 | — | — | |
| SCHEMBL23942125 | 0.72 | — | — | |
| SCHEMBL21616627 | 0.69 | — | — | |
| SCHEMBL2654680 | 0.67 | — | — | |
| SCHEMBL944891 | 0.67 | — | — | |
| SCHEMBL945428 | 0.67 | — | — | |
| SCHEMBL16792356 | 0.65 | ACHE (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694846-B1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | GILEAD SCIENCES INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| EP-2499126-A1 | FUSED BICYCLIC PYRIDINE AND PYRAZINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2396315-A1 | FUSED PYRIDINE AND PYRAZINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2011-12-21 | — | — | EP | disclosed |
| EP-2346878-A1 | FUSED PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2011-07-27 | — | — | EP | disclosed |
| WO-2011058113-A1 | FUSED BICYCLIC PYRIDINE AND PYRAZINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010092340-A1 | FUSED PYRIDINE AND PYRAZINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-08-19 | — | — | WO | disclosed |
| US-7745475-B2 | Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) | ASTRAZENECA AB (SE) | 2010-06-29 | — | — | US | disclosed |
| WO-2010061180-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010046639-A1 | FUSED PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-04-29 | — | — | WO | disclosed |
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| EP-1992623-A1 | Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes | Astra Zeneca AB (SE) | 2008-11-19 | — | — | EP | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | disclosed |